Drug Combo May Be Effective in Ovarian Cancer

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-nb2014-089
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Low Expression of KCNN3 May Affect Drug Resistance in Ovarian Cancer

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2018English

BCL2/MDM2 Inhibitor Combo Effective in AML

Cancer Discovery
Oncology
2019English

FOXD3 May Be a New Cellular Target Biomarker as a Hypermethylation Gene in Human Ovarian Cancer

Cancer Cell International
Cancer ResearchOncologyGenetics
2019English

HSPA1A, HSPA1L and TRAP1 Heat Shock Genes May Be Associated With Prognosis in Ovarian Epithelial Cancer

Oncology Letters
Cancer ResearchOncology
2019English

Combo Drug Strategy Tested for PDAC

Cancer Discovery
Oncology
2019English

Ovarian Cancer May Originate in the Fallopian Tube

Cancer Discovery
Oncology
2012English

Biomarkers in Ovarian Cancer: To Be or Not to Be

Cancer
Cancer ResearchOncology
2019English

Targeted Combo Effective for Refractory Ewing Sarcoma

Cancer Discovery
Oncology
2012English

Implementing Clinical Guidelines. Guidelines May Not Be Cost Effective.

BMJ
1993English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy